SCHEMBL838217

SCHEMBL838217

O=C(O)CCC[PH](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
MAPK1 P28482 1/20 0.50
ADRA1A P35348 1/20 0.50
SLC6A3 Q01959 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
ALDH1A1 P00352 1/20 0.46
ATM Q13315 1/20 0.44
KEAP1 Q14145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL8104984 0.98 HDAC3 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
Acetic Acid SCHEMBL10620271 0.94 HDAC3 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1838985 0.94 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13327139 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2963290 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10845864 0.92 HDAC3 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL15132444 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20859564 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11207545 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7624634 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156982-A1 METHOD OF FORMING PEPTIDE-COATED NANOPARTICLES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2024-05-16 US claimed
CN-112341493-B Mitochondrial targeting melatonin based on triphenylphosphine modification and preparation method and application thereof 重庆医药高等专科学校附属第一医院(重庆市职业病防治院 重庆市第六人民医院 重庆市中毒控制中心) 2023-08-15 CN claimed
CN-112341493-A Mitochondrial targeting melatonin modified based on triphenylphosphine and preparation method and application thereof 重庆医药高等专科学校附属第一医院(重庆市职业病防治院重庆市第六人民医院重庆市中毒控制中心) 2021-02-09 CN claimed
US-20250313552-A1 NICOTINATE ESTERS AND THERAPEUTIC METHODS OF USE THEREOF NEW FRONTIER BIO INC (US) 2025-10-09 US disclosed
US-20250235805-A1 LUBRICANT FOR FILTRATION CONTAINING ONIUM IONS TOKUYAMA CORPORATION (JP) 2025-07-24 US disclosed
US-20250215574-A1 SEMICONDUCTOR TREATMENT LIQUID FOR REMOVING RUTHENIUM SILICIDE TOKUYAMA CORPORATION (JP) 2025-07-03 US disclosed
CN-119948603-A Dry etching residue removing liquid 株式会社德山 2025-05-06 CN disclosed
US-20250084309-A1 SEMICONDUCTOR PROCESSING SOLUTION TOKUYAMA CORPORATION (JP) 2025-03-13 US disclosed
EP-4506982-A1 LUBRICANT FOR FILTRATION CONTAINING ONIUM IONS TOKUYAMA CORPORATION (JP) 2025-02-12 EP disclosed
CN-119144005-A Metal-based polymer nanoparticle antibacterial agent and preparation method and application thereof 哈尔滨工业大学 2024-12-17 CN disclosed
CN-118974895-A Filter lubricant containing onium ion 株式会社德山 2024-11-15 CN disclosed
EP-0541407-A1 Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1993-05-12 EP disclosed
EP-0159784-B1 CARBACYCLIN ANALOGUES THE UPJOHN COMPANY (US) 1989-06-07 EP disclosed
US-4683330-A ANTICOAGULANTS, ANTIULCER AGENTS THE UPJOHN COMPANY (US) 1987-07-28 US disclosed
US-4338316-A PROSTAGLANDIN F SERIES ANALOGUES IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-07-06 US disclosed
EP-0010360-B1 PROSTANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-06-02 EP disclosed
US-4306095-A USEABLE IN LUTEOLYSIS, INHIBITING BLOOD PLATELET AGGREGATION AND INHIBITING PRODUCTION OF GASTRIC ACID IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1981-12-15 US disclosed
US-4241215-A FOR LUTEOLYSIS, INHIBITING BLOOD PLATELET AGGREGATION, AND INHIBITING SECRETION OF GASTRIC JUICES IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1980-12-23 US disclosed
EP-0010360-A1 Prostane derivatives, processes for their preparation and their pharmaceutical compositions IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1980-04-30 EP disclosed
US-4071530-A Pyrrolidones and process for preparing them HOECHST AKTIENGESELLSCHAFT (DT) 1978-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313552-A1 NICOTINATE ESTERS AND THERAPEUTIC METHODS OF USE THEREOF NNT, NNMT, NAMPT HDAC3 230/4885HDAC4 397/4885HDAC1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.